Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Simcere Pharmaceutical Group has signed a definitive agreement to acquire a 70% equity interest in Wuhu Zhong Ren Pharmaceutical for a total cash consideration of RMB64.82 million.
Subscribe to our email newsletter
This transaction is consistent with Simcere’s strategy to focus on first-to-market and innovative new drugs and expand its anticancer product portfolio.